Cited by 296Glioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Yen, K E, Bittinger, M A, Su, S M, Fantin, V R·2010·Oncogene

DOI 10.1038/onc.2010.444

Open this paper in CoChat — free account

Abstract

The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-wide mutational analysis in glioblastoma represents a milestone event in cancer biology. The nature of the heterozygous, point mutations mapping to arginine residues involved in the substrate binding inspired several research teams to investigate their impact on the biochemical activity of these enzymes. Soon, it became clear that the mutations identified impaired the ability of IDH1 and IDH2 to catalyze the conversion of isocitrate to α-ketoglutarate (αKG), whereas conferring a gain of a novel enzymatic activity leading to the reduction of αKG to the metabolite D2-hydroxyglutarate (D-2HG). Across glioma as well as several hematologic malignancies, mutations in IDH1 and IDH2 have shown prognostic value. Several hypotheses implicating the elevated levels of D-2HG and tumorigenesis, and the therapeutic potential of targeting mutant IDH enzymes will be discussed.

Integrity signals

Registry

Crossref · 10.1038/onc.2010.444

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337

Flagged first, then by citations

Show all 63 references

1 of the 63 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 296

Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics
Xu, Y., Liu, L., Nakamura, A., Someya, S., Miyakawa, T., & Tanokura, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10337-7 · Cited by 47
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Maggio, I., Lodi, R., & Brandes, A. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00537-3 · Cited by 44
Molecular Pathogenesis of Low-Grade Glioma
Bready, D., & Placantonakis, D. G. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.011 · Cited by 40
Molecular Targets in Glioblastoma
Zorzan, M., Giordan, E., Redaelli, M., Caretta, A., & Mucignat‐Caretta, C. (2015) · Future Oncology · doi:10.2217/fon.15.22 · Cited by 38
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Ragon, B. K., & Dinardo, C. D. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0418-6 · Cited by 39
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
Salati, M., Caputo, F., Baldessari, C., Galassi, B., Grossi, F., Dominici, M., & Ghidini, M. (2020) · Cancers · doi:10.3390/cancers12113310 · Cited by 42
Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter
de Andrea, C. E., & Hogendoorn, P. C. W. (2011) · The Journal of Pathology · doi:10.1002/path.3003 · Cited by 35
In-VivoProton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists
Kim, H., Kim, S., Lee, H. H., & Heo, H. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.5.620 · Cited by 36
Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells
Gerecke, C., Schumacher, F., Berndzen, A., Homann, T., & Kleuser, B. (2019) · Epigenetics · doi:10.1080/15592294.2019.1666652 · Cited by 36
A d-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR
Xiao, D., Zhang, W., Guo, X., Liu, Y., Hu, C., Guo, S., Kang, Z., Xu, X., Ma, C., Gao, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27357-7 · Cited by 34
Association of TET1 expression with colorectal cancer progression
Tian, Y., Pan, F., Sun, X., Gan, M., Lin, A., Zhang, D., Zhu, Y., & Lai, M. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2016.1253767 · Cited by 34
Interplay of Sphingolipid Metabolism in Predicting Prognosis of GBM Patients: Towards Precision Immunotherapy
Wang, Q., Zheng, C., Hou, H., Bao, X., Tai, H., Huang, X., Li, Z., Li, Z., Wang, Q., Pan, Q., et al. (2023) · Journal of Cancer · doi:10.7150/jca.89338 · Cited by 35
2-Hydroxyglutarate as a Magnetic Resonance Biomarker for Glioma Subtyping
Esmaeili, M., Vettukattil, R., & Bathen, T. F. (2013) · Translational Oncology · doi:10.1593/tlo.12424 · Cited by 35
Magnetic resonance analysis of malignant transformation in recurrent glioma
Jalbert, L. E., Neill, E., Phillips, J. J., Lupo, J., Olson, M. P., Molinaro, A. M., Berger, M. S., Chang, S. M., & Nelson, S. J. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now008 · Cited by 35
IDH1-dependent α-KG regulates brown fat differentiation and function by modulating histone methylation
Kang, H. S., Lee, J. H., Oh, K., Lee, E., Han, B., Park, K.-Y., Suh, J. M., Min, J., Chi, S., Lee, S. C., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154173 · Cited by 33
Analysis of KIAA1549–BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas
Cruz, G. R., Oliveira, I. D., Moraes, L. D. S., Paniago, M. D. G., Alves, M. T. D. S., Capellano, A. M., Saba‐Silva, N., Cavalheiro, S., Cerutti, J. M., & de Toledo, S. R. C. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1398-1 · Cited by 32
Radiomics, Metabolic, and Molecular MRI for Brain Tumors
Kickingereder, P., & Andronesi, O. C. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1618600 · Cited by 31
Survival of the fittest: metabolic adaptations in cancer
Berardi, M. J., & Fantin, V. R. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.001 · Cited by 30
Self-citation
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
Koszarska, M., Bors, A., Feczko, A., Meggyesi, N., Bátai, Á., Csomor, J., Ádám, E., Kozma, A., Orbán, T. I., Lovas, N., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.736981 · Cited by 32
Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer
Rohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31
Intratumoral metabolic heterogeneity of colorectal cancer
Hirose, Y., & Taniguchi, K. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00139.2021 · Cited by 31
IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas
Qi, S.-Τ. (2011) · Oncology Reports · doi:10.3892/or.2011.1428 · Cited by 31
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing
Lee, J. H., Shin, D., Park, W. Y., Shin, N., Kim, A., Lee, H. J., Kim, Y. K., Choi, K. U., Kim, J. Y., Yang, Y. I., et al. (2017) · World Journal of Surgical Oncology · doi:10.1186/s12957-017-1144-1 · Cited by 30
Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach
Díaz, C., González‐Olmedo, C., Díaz-Beltrán, L., Camacho, J., García, P. M., Martín-Blázquez, A., Fernández-Navarro, M., Granados, A. L. O., Gálvez-Montosa, F., Marchal, J. A., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13216 · Cited by 29
The impact of RNA binding proteins and the associated long non-coding RNAs in the TCA cycle on cancer pathogenesis
Shen, T., Wang, H., Tang, B., Zhu, G., & Wang, X. (2023) · RNA Biology · doi:10.1080/15476286.2023.2216562 · Cited by 29
Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer
Qiao, S., Lu, W., Glorieux, C., Li, J., Zeng, P., Meng, N., Zhang, H., Wen, S., & Huang, P. (2021) · Oncogene · doi:10.1038/s41388-021-01968-2 · Cited by 30
RETRACTED ARTICLE: Myricetin nanoliposomes induced SIRT3-mediated glycolytic metabolism leading to glioblastoma cell death
Wang, G., Wang, J., Wang, Y., Shi, F., Jing, G., & Fu, X. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1489825 · Cited by 28
Retracted
Metabolo-epigenetic interplay provides targeted nutritional interventions in chronic diseases and ageing
de Cedrón, M. G., Palomares, R. M., & de Molina, A. R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169168 · Cited by 34
IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells
Matsunaga, H., Futakuchi-Tsuchida, A., Takahashi, M., ISHIKAWA, T., Tsuji, M., & Ando, O. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.002 · Cited by 28
Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”
Dzobo, K. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0206 · Cited by 29
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Liu, X., Qiao, Y., Ting, X., & Si, W. (2020) · PubMed Central · Cited by 26
Correlation of Metabolic Profiles of Plasma and Cerebrospinal Fluid of High-Grade Glioma Patients
Rogachev, A. D., Alemasov, N. A., Иванисенко, В. А., Ivanisenko, N. V., Gaisler, E. V., Oleshko, O. S., Cheresiz, S. V., Mishinov, S. V., Stupak, V. V., & Pokrovsky, А. G. (2021) · Metabolites · doi:10.3390/metabo11030133 · Cited by 29
Non–small cell lung cancers with isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) mutations
Toth, L. N., Abreu, F. B. D., & Tafe, L. J. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.04.014 · Cited by 28
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d ‐2‐hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma
Mohammad, N., Wong, D., Lum, A. M., Lin, J., Ho, J., Lee, C., & Yip, S. S. F. (2019) · Histopathology · doi:10.1111/his.14018 · Cited by 26
The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma
Doğan, S., Frosina, D., Fayad, M., Basili, T., Alemar, B., Rosenblum, M. K., Tang, L. H., Hameed, M., Xu, B., Ghossein, R. A., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0126-3 · Cited by 26
Bioactive atropisomers: Unraveling design strategies and synthetic routes for drug discovery
Liu, S., Zhao, Q., Liu, X., Gamble, A. B., Huang, W., Yang, Q., & Han, B. (2024) · Medicinal Research Reviews · doi:10.1002/med.22037 · Cited by 29
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
Persico, P., Lorenzi, E., Losurdo, A., Dipasquale, A., Muzio, A. D., Navarria, P., Pessina, F., Politi, L. S., Lombardi, G., Santoro, A., et al. (2022) · Cancers · doi:10.3390/cancers14051125 · Cited by 25
The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma
Klingenschmid, J., Krigers, A., Pinggera, D., Kerschbaumer, J., Thomé, C., & Freyschlag, C. F. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04001-y · Cited by 25
Functional mechanism and clinical implications of miR-141 in human cancers
Luo, Q., Tian, Y., Qu, G., Kun-Huang, & Luo, S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110354 · Cited by 26
The emerging potential role of p62 in cancer treatment by regulating metabolism
Zhang, X., Dai, M., Li, S., Li, M., Cheng, B., Ma, T., & Zhou, Z. G. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.05.004 · Cited by 30
Mutated IDH1 Is a Favorable Prognostic Factor for Type 2 Gliomatosis Cerebri
Kwon, M. J., Kim, S. T., Kwon, M. J., Kong, D., Lee, D., Park, S., Kang, S. Y., Song, J., Nam, D., Kato, Y., et al. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00532.x · Cited by 25
Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER
Berrington, A., Voets, N., Plaha, P., Larkin, S. J., McCullagh, J., Stacey, R. J., Yildirim, M., Schofield, C. J., Jezzard, P., Cadoux-Hudson, T. A. D., et al. (2016) · Tomography · doi:10.18383/j.tom.2016.00139 · Cited by 25
The Role of Forkhead Box Proteins in Acute Myeloid Leukemia
Gurnari, C., Falconi, G., Bellis, E. D., Voso, M. T., & Fabiani, E. (2019) · Cancers · doi:10.3390/cancers11060865 · Cited by 26
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α
Semukunzi, H., Roy, D., Li, H., Khan, G. J., Lyu, X., Yuan, S., & Lin, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.083 · Cited by 25
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Mehrjardi, N. Z., Hänggi, D., & Kahlert, U. D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03196-0 · Cited by 23
The metabolic addiction of cancer stem cells
Sahoo, O. S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Alqahtani, M. S., Abbas, M. A. E., Dhar, R., & Karmakar, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955892 · Cited by 26
Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
Kotredes, K. P., Razmpour, R., Lutton, E. M., Alfonso‐Prieto, M., Ramirez, S. H., & Gamero, A. M. (2019) · Oncotarget · doi:10.18632/oncotarget.26848 · Cited by 24
Targeting Cancer Metabolism and Current Anti-Cancer Drugs
Sukjoi, W., Ngamkham, J., Attwood, P. V., & Jitrapakdee, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_2 · Cited by 23
DNA Hydroxymethylation in Smoking-Associated Cancers
Nia, A. B., Caceres, A., & Tommasi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052657 · Cited by 25
TET family proteins: new players in gliomas
Bian, E., Zong, G., Xie, Y., Meng, X., Huang, C., Li, J., & Zhao, B. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1328-7 · Cited by 24
Clinical developments in epigenetic-directed therapies in acute myeloid leukemia
Pan, D., Rampal, R. K., & Mascarenhas, J. O. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001245 · Cited by 23
Pharmacological characterization of TQ 05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
Gao, M., Zhu, H., Li, F., Li, Y., Bao, X., Fu, H., Quan, H., Wang, L., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.14152 · Cited by 21
Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer
Li, W., Xiao, M., Zhang, D., Yu, D., Yang, R., Li, X., & Yao, Y. (2014) · Gene · doi:10.1016/j.gene.2014.05.070 · Cited by 23
Genome-Based Classification and Therapy of Prostate Cancer
Angeles, A. K., Bauer, S., Ratz, L., Klauck, S. M., & Sültmann, H. (2018) · Diagnostics · doi:10.3390/diagnostics8030062 · Cited by 23
IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway
Zhang, L., Qi, M., Feng, T., Hu, J., Wang, L., Li, X., Gao, W. Q., Liu, H., Jiao, M., Wu, Z., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.001 · Cited by 21
A double surrogate approach for the quantitation of 2-Hydroxyglutarate – An oncometabolite in human brain tumors via LC-MS/MS
Yin, F. Q., Keller, J., Kraus, D. H., Mangus, H., Li, F., & Liu, G. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112916 · Cited by 21
IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation
Landberg, N., Köhnke, T., Feng, Y., Nakauchi, Y., Fan, A. C., Linde, M. H., Karigane, D., Lim, K. S., Sinha, R., Malcovati, L., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0195 · Cited by 23
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma
Raghunathan, A., Olar, A., Vogel, H. S., Parker, J. R., Coventry, S. C., Debski, R., Albarracin, C. T., Aldape, K., Cahill, D. P., Powell, S. Z.-E., et al. (2012) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2011.11.003 · Cited by 21
Biliary tract cancer prognostic and predictive genomics
Mondaca, S., Nervi, B., Pinto, M. P., & Abou‐Alfa, G. K. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.07.06 · Cited by 22
Clinical Proteomics of Biofluids in Haematological Malignancies
Dunphy, K., O’Mahoney, K., Dowling, P., O’Gorman, P., & Bazou, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158021 · Cited by 21
The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes
Zahr, A. A., Aldin, E. S., Barbarotta, L., Podoltsev, N. A., & Zeidan, A. M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1061936 · Cited by 20
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
Pan, D., & Richter, J. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819127 · Cited by 19
ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells
Davis, M. I., Pragani, R., Popovici-Müller, J. V., Größ, S., Thorne, N., Salituro, F., Fantin, V. R., Straley, K. S., Su, M. S. S., Dang, L., et al. (2013) · Europe PMC (PubMed Central) · Cited by 19
Self-citation
Metabolic Alterations at the Crossroad of Aging and Oncogenesis
Raffaghello, L., & Longo, V. D. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.01.003 · Cited by 19
From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
Gurnari, C., Voso, M. T., Maciejewski, J. P., & Visconte, V. (2020) · Cancers · doi:10.3390/cancers12020357 · Cited by 18
Interplay Between Glucose Metabolism and Chromatin Modifications in Cancer
Ma, R., Wu, Y., Li, S., & Yu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.654337 · Cited by 18
Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?
Goryńska, P. Z., Chmara, K., Kupcewicz, B., Goryński, K., Jaroch, K., Pa̧czkowski, D., Furtak, J., Harat, M., & Bojko, B. (2022) · Cancers · doi:10.3390/cancers14020312 · Cited by 16
Targeting IDH1/IDH2 mutations in gliomas
de la Fuente, M. I. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001111 · Cited by 18
The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
Liu, L., Hu, K., Feng, J., Wang, H., Fu, S., Wang, B., Wang, L., Xu, Y., Yu, X., & Huang, H. (2021) · BMC Cancer · doi:10.1186/s12885-020-07744-x · Cited by 17
Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T
Shams, Z., van der Kemp, W. J. M., Emir, U. E., Dankbaar, J. W., Snijders, T. J., Vos, F. D., Klomp, D. W. J., Wijnen, J. P., & Wiegers, E. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.718423 · Cited by 17
A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: Novel avenues for biochemical and therapeutic studies
Kranendijk, M., Salomons, G. S., Gibson, K. M., SCHAFTINGEN, E. V., Jakobs, C., & Struys, E. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.006 · Cited by 17
1H-NMR Chemical Shifts and Coupling Constants for Brain Metabolites
Govind, V. (2016) · Wiley eBooks · doi:10.1002/9780470034590.emrstm1530 · Cited by 17
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer
Tang, J., Chang, C., Lin, P., & Chang, J. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2011.10.023 · Cited by 16
Role of isocitrate dehydrogenase in glioma
Alexander, B. M., & Mehta, M. P. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.134 · Cited by 16
Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC
Sinicropi-Yao, S. L., Amann, J. M., Lopez, D. L. Y., Cerciello, F., Coombes, K. R., & Carbone, D. P. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.162 · Cited by 16
Transcriptional regulation of metabolism in disease: From transcription factors to epigenetics
Hawkins, L. J., Al-attar, R., & Storey, K. B. (2018) · PeerJ · doi:10.7717/peerj.5062 · Cited by 17
IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5
Yan, B., Hu, Y., Ma, T., & Wang, Y. (2018) · Open Biology · doi:10.1098/rsob.180086 · Cited by 17
On the Genesis of Neuroblastoma and Glioma
de Weille, J. R. (2014) · International Journal of Brain Science · doi:10.1155/2014/217503 · Cited by 15
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Romanidou, O., Kotoula, V., & Fountzilas, G. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20101 · Cited by 15
2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
Wahl, D. R., & Venneti, S. (2015) · Brain Pathology · doi:10.1111/bpa.12309 · Cited by 14
A Novel COLD-PCR/FMCA Assay Enhances the Detection of Low-abundance IDH1 Mutations in Gliomas
Pang, B., Durso, M. B., Hamilton, R. L., & Nikiforova, M. N. (2013) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31826c7ff8 · Cited by 14
Application of metabolomics in sarcoma: From biomarkers to therapeutic targets
Min, L., Choy, E., Tu, C., Hornicek, F. J., & Duan, Z. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.003 · Cited by 14
Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients
Acquaviva, G., Visani, M., de Biase, D., Marucci, G., Franceschi, E., Tosoni, A., Brandes, A. A., Rhoden, K. J., Pession, A., & Tallini, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22222-y · Cited by 14
Put in a “Ca2+ll” to Acute Myeloid Leukemia
Lewuillon, C., Laguillaumie, M.-O., Quesnel, B., Idziorek, T., Touil, Y. S., & Lemonnier, L. (2022) · Cells · doi:10.3390/cells11030543 · Cited by 16
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas
Fujii, Y., Ogasawara, S., Oki, H., Liu, X., Kaneko, M. K., Takano, S., & Kato, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.070 · Cited by 13
Optimizing the Chemical Recognition Process of a Fluorescent Chemosensor for α-Ketoglutarate
He, Y., Guo, Z., Jin, P., Jiao, C., Tian, H., & Zhu, W. (2015) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.5b00263 · Cited by 13
The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects
Singh, R., & Mills, I. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704353 · Cited by 13
Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients
Zhang, H., Guo, X., Dai, J., Wu, Y., Ge, N., Yang, Y., Ji, J., & Zhang, H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0278-z · Cited by 13
Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers
Lee, W., Chen, K., Chen, H., & Chen, C. Y. (2014) · BioMed Research International · doi:10.1155/2014/364625 · Cited by 13
Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer
Bhatia, V., & Ateeq, B. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.001 · Cited by 14
Genetic variations in genes of metabolic enzymes predict postoperational prognosis of patients with colorectal cancer
Dong, G., He, X., Chen, Y., Cao, H., Wang, J., Liu, X., Wang, S., Wan, S., & Xing, J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0442-x · Cited by 13
Quantitative detection ofIDH2mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations inNPM1gene
Ježíšková, I., Rázga, F., Tošková, M., Dvořáková, D., Timilsina, S., Mayer, J., & Ráčil, Z. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.727414 · Cited by 12
A New Frontier in Personalized Cancer Therapy: Mapping Molecular Changes
Kasaian, K., & Jones, S. J. M. (2011) · Future Oncology · doi:10.2217/fon.11.63 · Cited by 12
Molecular prognostic factors in glioblastoma: state of the art and future challenges
Xavier‐Magalhães, A., Nandhabalan, M., Jones, C., & Costa, B. M. (2013) · CNS Oncology · doi:10.2217/cns.13.48 · Cited by 11
Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification
Aydemirli, M. D., Snel, M., van Wezel, T., Ruano, D., Obbink, C. M. H., van den Hout, W. B., Schepers, A., & Morreau, H. M. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.293 · Cited by 12
Quantitation of Ivosidenib in Human Plasma Via LC–MS/MS and its Application in Clinical Trials
Yin, F. Q., Yu, S., Narayanaswamy, R., Mangus, H., McCourt, E., & Liu, G. (2021) · Bioanalysis · doi:10.4155/bio-2021-0034 · Cited by 11
Development of simultaneous quantitative analysis of tricarboxylic acid cycle metabolites to identify specific metabolites in cancer cells by targeted metabolomic approach
Yamamoto, T., Sato, K., Yamaguchi, M., Mitamura, K., & Taga, A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.072 · Cited by 14
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor
Liang, Q., Wang, B., Zou, F., Guo, G., Wang, W., Wang, W., Liu, Q., Shen, L., Hu, C., Wang, W., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115411 · Cited by 10
The LncRNA FEZF1-AS1 promotes tumor proliferation in colon cancer by regulating the mitochondrial protein PCK2
WANG, H., Wu, Y., WANG, Z., CHEN, Y., MO, J., GUAN, W., ZHANG, Y., & Yao, H. (2021) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.03553 · Cited by 10
A Förster resonance energy transfer-based d-2-hydroxyglutarate biosensor
Xiao, D., Xu, X., Gao, K., Wang, M., Zhang, W., Lü, C., Wang, X., Wang, Q., Xu, P., Ma, C., et al. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133681 · Cited by 10

Authors: Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R.
Affiliations: Agios Pharmaceuticals (United States) (US)
Corresponding author: Fantin, V R
ORCID: Yen, K E
Fantin, V R
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2010-10-25
Volume: 29
Issue: 49
Pages: 6409-6417
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2010.444
OpenAlex: W2002134084
Cited by: 296
References: 63
Citations by year: 2026: 3 · 2025: 8 · 2024: 11 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 23 · 2016: 16 · 2015: 16 · 2014: 18 · 2013: 29 · 2012: 27
FWCI: 2.93
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: IDH mutation, IDH1, IDH2, glioblastoma, glioma, hematologic malignancies, gain-of-function mutations, alpha-ketoglutarate, prognostic factors, carcinogenesis
MeSH terms: Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Oncogenes, Biomarkers, Tumor, Central Nervous System Neoplasms, Point Mutation, Hematologic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks